{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:25:03Z","timestamp":1780597503242,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Osteogenesis Imperfecta Foundation Michael Geisman Fellowship"},{"name":"Pediatric Endocrinology Society Research Fellowship"},{"name":"Howard Hughes Medical Institute Medical Research Fellows Program"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AR063813"],"award-info":[{"award-number":["AR063813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AR53237"],"award-info":[{"award-number":["AR53237"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AR062326"],"award-info":[{"award-number":["AR062326"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bone.2016.06.005","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T11:22:17Z","timestamp":1465903337000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1 +\/mov13 mouse model of type I Osteogenesis Imperfecta"],"prefix":"10.1016","volume":"90","author":[{"given":"Christina M.","family":"Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Eun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Spevak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele L.","family":"Boskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zurakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Robling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Warman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.06.005_bb0005","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00223-012-9588-3","article-title":"Recent advances in osteogenesis imperfecta","volume":"90","author":"Cundy","year":"2012","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.06.005_bb0010","article-title":"Osteogenesis Imperfecta Type I caused by COL1A1 deletions","author":"Bardai","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.06.005_bb0015","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/jbmr.1942","article-title":"Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1","volume":"28","author":"Ben Amor","year":"2013","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.06.005_bb0020","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005088.pub2","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Phillipi","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2016.06.005_bb0025","first-page":"653","article-title":"Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta","volume":"24","author":"Atta","year":"2014","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"10.1016\/j.bone.2016.06.005_bb0030","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2016.06.005_bb0035","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.06.005_bb0040","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/1471-2474-14-251","article-title":"Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study","volume":"14","author":"Ljunggren","year":"2013","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2016.06.005_bb0045","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jbspin.2013.05.001","article-title":"Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study","volume":"81","author":"Rajzbaum","year":"2014","journal-title":"Joint bone Spine Rev. Rhum."},{"key":"10.1016\/j.bone.2016.06.005_bb0050","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.06.005_bb0055","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.06.005_bb0060","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2016.06.005_bb0065","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.06.005_bb0070","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.06.005_bb0075","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.06.005_bb0080","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/320365a0","article-title":"Retrovirus insertion inactivates mouse alpha 1(I) collagen gene by blocking initiation of transcription","volume":"320","author":"Hartung","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bone.2016.06.005_bb0085","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1073\/pnas.87.18.7145","article-title":"Transgenic mouse model of the mild dominant form of osteogenesis imperfecta","volume":"87","author":"Bonadio","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2016.06.005_bb0090","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jor.1100140320","article-title":"Type-I collagen mutation compromises the post-yield behavior of Mov13 long bone","volume":"14","author":"Jepsen","year":"1996","journal-title":"J. Orthop. Res. Off. Publ. Orthop. Res. Soc."},{"key":"10.1016\/j.bone.2016.06.005_bb0095","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nm.2388","article-title":"Lrp5 functions in bone to regulate bone mass","volume":"17","author":"Cui","year":"2011","journal-title":"Nat. Med."},{"issue":"52","key":"10.1016\/j.bone.2016.06.005_bb0100","first-page":"54","article-title":"Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT)","volume":"29","author":"Truett","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.bone.2016.06.005_bb0105","doi-asserted-by":"publisher","first-page":"23698","DOI":"10.1074\/jbc.M601000200","article-title":"The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment","volume":"281","author":"Sawakami","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.06.005_bb0110","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bone.2016.04.011","article-title":"Bone mineral properties in growing Col1a2(+\/G610C) mice, an animal model of osteogenesis imperfecta","volume":"87","author":"Masci","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.06.005_bb0115","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","article-title":"An analysis of variance test for normality","volume":"52","author":"Shapiro","year":"1965","journal-title":"Biometrika"},{"key":"10.1016\/j.bone.2016.06.005_bb0120","series-title":"Biometry: The Principles and Practice of Statistics in Biological Research","author":"Sokal","year":"1995"},{"key":"10.1016\/j.bone.2016.06.005_bb0125","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0021-9290(97)00088-2","article-title":"Type I collagen mutation alters the strength and fatigue behavior of Mov13 cortical tissue","volume":"30","author":"Jepsen","year":"1997","journal-title":"J. Biomech."},{"key":"10.1016\/j.bone.2016.06.005_bb0130","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1172\/JCI116756","article-title":"A murine skeletal adaptation that significantly increases cortical bone mechanical properties. Implications for human skeletal fragility","volume":"92","author":"Bonadio","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2016.06.005_bb0135","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216301570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216301570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T06:56:40Z","timestamp":1536649000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216301570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":27,"alternative-id":["S8756328216301570"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.06.005","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1+\/mov13 mouse model of type I Osteogenesis Imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}